RNA (Atrium Therapeutics) Total Operating Expense: $85.81 Mil (TTM As of Mar. 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $13.15
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics Total Operating Expense?

Atrium Therapeutics RNA +3.21% 12 Total Operating Expense is $85.81 Mil as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Atrium Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was $36.92 Mil. Atrium Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $85.81 Mil.

Atrium Therapeutics Total Operating Expense Related Terms

Atrium Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics Total Operating Expense Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Total Operating Expense
16.15 24.12 95.43

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial 9.22 9.03 0.00 48.89 36.92
RNA
12GF Score
Atrium Therapeutics Inc RNA
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $85.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $85.81 Mil mean?
Atrium Therapeutics (RNA) has a Total Operating Expense of $85.81 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Atrium Therapeutics and its competitors.
Is Atrium Therapeutics' Total Operating Expense too high?
Atrium Therapeutics' current Total Operating Expense is $85.81 Mil. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Total Operating Expense compare to RNAC and KROS?
Atrium Therapeutics' Total Operating Expense of $85.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current Total Operating Expense is $85.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Total Operating Expense of $85.81 Mil. The current Total Operating Expense is $85.81 Mil. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Total Operating Expense is $85.81 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.15
Price